A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Sta - Genesis Health System

Colon Cancer: A021502 (Adjuvant Treatment)

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Objective

This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

For more information please visit the National Cancer Institute.

LOCATIONS:

1. Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number: 563-421-1900

2. Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3. Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number: 563-345-4325

Principal Investigator(s)
David Spector, MD, PhD

Clinical Trial Categories

  • Colon
  • Cancer
  • Gastro-Intestinal
Sponsor(s)
Alliance for Clinical Trials in Oncology
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email